About moderna inc. - MRNA
MRNA At a Glance
| Phone | 1-617-714-6500 | Revenue | 3.24B | |
| Industry | Biotechnology | Net Income | -3,561,000,000.00 | |
| Sector | Health Technology | Employees | 5,800 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
MRNA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.934 |
| Price to Book Ratio | 1.472 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.579 |
| Enterprise Value to Sales | 2.994 |
| Total Debt to Enterprise Value | 0.077 |
MRNA Efficiency
| Revenue/Employee | 557,931.034 |
| Income Per Employee | -613,965.517 |
| Receivables Turnover | 5.466 |
| Total Asset Turnover | 0.199 |
MRNA Liquidity
| Current Ratio | 3.671 |
| Quick Ratio | 3.618 |
| Cash Ratio | 3.185 |
MRNA Profitability
| Gross Margin | 48.918 |
| Operating Margin | -121.91 |
| Pretax Margin | -111.465 |
| Net Margin | -110.043 |
| Return on Assets | -21.868 |
| Return on Equity | -28.77 |
| Return on Total Capital | -30.572 |
| Return on Invested Capital | -26.691 |
MRNA Capital Structure
| Total Debt to Total Equity | 6.853 |
| Total Debt to Total Capital | 6.413 |
| Total Debt to Total Assets | 5.282 |
| Long-Term Debt to Equity | 6.513 |
| Long-Term Debt to Total Capital | 6.095 |
Moderna Inc. in the News
Pfizer shares sink after it resets 2024 COVID expectations
Pfizer, Inc. on Wednesday forecast 2024 sales that could be as much as $5 billion below Wall Street expectations, driving shares down 9% to a 10-year low.
Aflac CEO says company adapted to health care in a 'post-COVID world'
The insurance industry has made some changes in the wake of COVID-19, and as patients needs evolve with time and medical recommendations, Aflac CEO Dan Amos said.
Moderna says updated COVID-19 vaccine offers 'strong immune response' to new variant
Moderna says its updated coronavirus vaccine offers a “strong" response to a new COVID-19 variant that is being monitored by the CDC and WHO.
Vaccine makers see stock price boost on Biden admin COVID shot push
News that the Biden administration is planning to push for Americans to get the updated COVID vaccines this fall caused several vaccine manufacturers' stock prices to rise Monday.
Moderna looks to inspire ‘revolution’ in cancer treatments: CEO
Moderna CEO Stéphane Bancel explains how technology from a promising new melanoma vaccine with Merck could help treat and defeat other diseases like lung, prostate and breast cancers.
Moderna stock tumbles after quarterly earnings show revenue declines
COVID-19 vaccine maker Moderna's shares fell on Thursday following the release of the company's third-quarter earnings, which showed a decline in revenue.
China approves Livzon Pharmaceutical's COVID vaccine as a booster
With COVID cases on the rise in China, the government has approved Livzon Pharmaceutical's COVID-19 vaccine as a booster, in hopes of having as many people boosted as possible.
CDC approves updated COVID-19 vaccines targeting omicron variant
The Centers for Disease Control and Prevention gave final approval to updated COVID-19 vaccines targeting the dominant omicron variant on Thursday.
U.S. begins rolling out COVID vaccines for young children
According to the White House's COVID-19 response coordinator Dr. Ashish Jha, the U.S has begun distributing COVID-19 vaccines for children as young as six months.
FDA panel recommends Pfizer and Moderna COVID-19 vaccines for children as young as 6 months old
Pfizer and Moderna's vaccines for children as young as 6 months old could be available next week after an FDA advisory panel recommended them on Wednesday.